Information Provided By:
Fly News Breaks for November 21, 2016
AMED
Nov 21, 2016 | 07:20 EDT
Oppenheimer analyst Michael Wiederhorn continues to believe Amedisys' story is on track to rebound as the HCHB implementation nears completion and as the lagging short-term impact from the implementation wears off. The analyst says the company continues to focus on the cost opportunities, but top-line trends also remain favorable through organic growth and M&A. Wiederhorn believes the recent weakness in the stock represents an opportunity for longer-term investors, and reiterates an Outperform rating and $50 price target on the shares.
News For AMED From the Last 2 Days
There are no results for your query AMED